NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $320.35 million. The Company’s portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. It currently has negative earnings. The firm is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer ; and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors.
The stock of Strongbridge Biopharma plc (NASDAQ:SBBP) is a huge mover today! The stock decreased 5.19% or $0.35 during the last trading session, reaching $6.4. About 111,655 shares traded. Strongbridge Biopharma plc (NASDAQ:SBBP) has declined 15.09% since December 4, 2016 and is downtrending. It has underperformed by 31.79% the S&P500.The move comes after 8 months negative chart setup for the $254.80 million company. It was reported on Dec, 4 by Barchart.com. We have $6.08 PT which if reached, will make NASDAQ:SBBP worth $12.74 million less.
The stock decreased 2.48% or $0.22 during the last trading session, reaching $8.64. About 577,426 shares traded. NewLink Genetics Corporation (NLNK) has risen 49.90% since December 4, 2016 and is uptrending. It has outperformed by 33.20% the S&P500.
Great Point Partners Llc holds 1.44% of its portfolio in NewLink Genetics Corporation for 1.09 million shares. Bogle Investment Management L P De owns 443,256 shares or 0.24% of their US portfolio. Moreover, Endurant Capital Management Lp has 0.18% invested in the company for 84,598 shares. The New York-based Orbimed Advisors Llc has invested 0.14% in the stock. Campbell & Co Investment Adviser Llc, a Maryland-based fund reported 12,929 shares.
Analysts await NewLink Genetics Corporation (NASDAQ:NLNK) to report earnings on February, 27. They expect $-0.69 earnings per share, down 50.00% or $0.23 from last year’s $-0.46 per share. After $-0.69 actual earnings per share reported by NewLink Genetics Corporation for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States, Sweden, and Cayman Islands. The company has market cap of $254.80 million. The firm offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. It currently has negative earnings. It is also involved in developing Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical development for the treatment of endogenous CushingÂ’s syndrome; and Veldoreotide, a novel somatostatin analogue that is in Phase II clinical development to treat acromegaly.
Among 3 analysts covering Strongbridge Biopharma (NASDAQ:SBBP), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Strongbridge Biopharma has $21 highest and $18 lowest target. $19.50’s average target is 204.69% above currents $6.4 stock price. Strongbridge Biopharma had 3 analyst reports since November 10, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, November 10 by Stifel Nicolaus. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, January 25. The company was initiated on Tuesday, November 10 by JMP Securities.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.